Psychiatry and Neurology, Neurology · Sumter, SC
NPI
1598922130
Since 2008
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
385 W Wesmark Blvd
Sumter, SC, 29150
Phone (803) 774-8240
Groups this clinician bills Medicare through
Medicare paid, 2024
$465K
48,772 services
Medicare patients, 2024
927
Average age 73
Drug cost, 2024
$8.0M
6,805 prescriptions
Company payments, 2025
$162K
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John K Baker was code J0585 (injection, onabotulinumtoxina, 1 unit), 38,100 times for 62 patients. In total John K Baker billed 48,772 services in 106 codes, and Medicare paid $465K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-06-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 38,100 | 62 | $4.55 | $173K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,344 | 747 | $11.18 | $15K |
| 99213 Office E&M - Established | Office | 881 | 578 | $56.74 | $50K |
| A9577 Injection, gadobenate dimeglumine (multihance), per ml | Office | 602 | 69 | $1.35 | $812 |
| 99214 Office E&M - Established | Office | 499 | 337 | $79.91 | $40K |
| 36415 Venipuncture Blood Collection | Office | 288 | 241 | $8.51 | $2,450 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 221 | 48 | $0.68 | $149 |
| 80048 Clinical Chemistry | Office | 188 | 169 | $8.29 | $1,559 |
| 80076 Clinical Chemistry | Office | 153 | 137 | $8.01 | $1,226 |
| 85025 Blood Count | Office | 153 | 135 | $7.61 | $1,164 |
| 84443 Clinical Chemistry | Office | 145 | 142 | $16.46 | $2,387 |
| 84439 Clinical Chemistry | Office | 145 | 141 | $8.84 | $1,282 |
| 99204 Office E&M - New | Office | 141 | 141 | $107.72 | $15K |
| 64615 Musculoskeletal | Office | 138 | 45 | $103.57 | $14K |
| 99205 Office E&M - New | Office | 138 | 138 | $144.76 | $20K |
By year: 2022 $471K for 44,785 services; 2023 $491K for 50,649 services; 2024 $465K for 48,772 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 288 | 241 | $8.51 | $2,450 |
| 80048 Clinical Chemistry | 188 | 169 | $8.29 | $1,559 |
| 85025 Blood Count | 153 | 135 | $7.61 | $1,164 |
| 80076 Clinical Chemistry | 153 | 137 | $8.01 | $1,226 |
| 84439 Clinical Chemistry | 145 | 141 | $8.84 | $1,282 |
| 84443 Clinical Chemistry | 145 | 142 | $16.46 | $2,387 |
| 82607 Clinical Chemistry | 87 | 85 | $14.78 | $1,286 |
| 85652 Clinical Chemistry | 74 | 73 | $2.65 | $196 |
| 83735 Clinical Chemistry | 38 | 33 | $6.57 | $250 |
| 84100 Clinical Chemistry | 35 | 31 | $4.65 | $163 |
Medicare prescription drug claims, 2024
In 2024, the drug John K Baker prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 427 prescriptions and refills. In total John K Baker wrote 6,805 Medicare prescriptions that cost $8.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 427 | 832 | 131 | $16K |
| Donepezil Hcl Generic | 385 | 831 | 131 | $4,577 |
| Gabapentin Generic | 282 | 485 | 85 | $6,922 |
| Levetiracetam Generic | 269 | 497 | 62 | $9,749 |
| Memantine Hcl Generic | 248 | 492 | 76 | $8,391 |
| Primidone Generic | 240 | 458 | 72 | $6,039 |
| Clonazepam Generic | 194 | 212 | 34 | $1,033 |
| Pregabalin Generic | 183 | 233 | 45 | $5,350 |
| Nortriptyline Hcl Generic | 173 | 272 | 57 | $3,478 |
| Rytary Carbidopa/Levodopa | 169 | 226 | 35 | $204K |
| Topiramate Generic | 150 | 275 | 44 | $1,399 |
| Lacosamide Generic | 143 | 190 | 44 | $14K |
| Quetiapine Fumarate Generic | 125 | 256 | 45 | $2,938 |
| Doxepin Hcl Generic | 106 | 179 | 32 | $3,746 |
| Austedo Xr Deutetrabenazine | 94 | 94 | 11 | $688K |
Brand drugs: 1,446 claims; generic drugs: 5,308 claims; opioid claims: 97.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John K Baker $162K ($162K in general payments such as food, travel and fees) from 29 companies. The largest payer was Pfizer Inc. with $29K.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 39 | $29K |
| Neurocrine BioSciences, Inc. NBIX | 45 | $27K |
| Otsuka America Pharmaceutical, Inc. 4578.T | 25 | $18K |
| Amgen Inc. AMGN | 22 | $15K |
| Teva Pharmaceuticals USA, Inc. TEVA | 52 | $13K |
| EMD Serono, Inc. MRK.DE | 10 | $13K |
| TG Therapeutics, Inc. TGTX | 24 | $13K |
| Abbvie Inc. ABBV | 41 | $9,223 |
| E.R. Squibb & Sons, L.L.C. BMY | 9 | $7,372 |
| UCB, Inc. UCB.BR | 24 | $6,911 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.